The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity

References

• Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293(23), 2873–2883 (2005).
   PubMed Web of Science ®Google Scholar
• Anonymous. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch. Pediatr. Adolesc. Med. 164(2), 116–123 (2010).
   PubMedGoogle Scholar
• Yanovski JA, Krakoff J, Salaita CG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 60(2), 477–485 (2011).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012).
   PubMed Web of Science ®Google Scholar
• Göke R, Fehmann HC, Linn T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268(26), 19650–19655 (1993).
   PubMed Web of Science ®Google Scholar
• Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med. Sci. Monit. 11(8), RA271–RA278 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 281(1), E155–E161 (2001).
   PubMed Web of Science ®Google Scholar
• Grill HJ, Hayes MR. The nucleus tractussolitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int. J. Obes. (Lond.) 33(Suppl. 1), S11–S15 (2009).
   Google Scholar
• Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract. 97(2), 258–266 (2012).
   PubMed Web of Science ®Google Scholar
• Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl. Physiol. Nutr. Metab. 37(5), 893–899 (2012).
   PubMedGoogle Scholar
• Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care 27(8), 1915–1921 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Klaff LJ, Schwartz S et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33(6), 1173–1175 (2010).
   PubMed Web of Science ®Google Scholar
• Dushay J, Gao C, Gopalakrishnan GS et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care 35(1), 4–11 (2012).
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701), 1606–1616 (2009).
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N et al.; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond). 36(6), 843–854 (2012).
   PubMed Web of Science ®Google Scholar
• Kelly AS, Metzig AM, Rudser KD et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 20(2), 364–370 (2012).
   PubMed Web of Science ®Google Scholar
• Kelly AS, Rudser KD, Nathan BM et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 167(4), 355–360 (2013).
   PubMed Web of Science ®Google Scholar
• Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens. 23(3), 334–339 (2010).
   PubMed Web of Science ®Google Scholar
• Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res. Clin. Pract. 98(2), 271–284 (2012).
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in Type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33(11), 2349–2354 (2010).
   PubMed Web of Science ®Google Scholar
• Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol. Ther. 14(10), 904–911 (2012).
   PubMed Web of Science ®Google Scholar
• Wenten M, Gaebler JA, Hussein M et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet. Med. 29(11), 1412–1418 (2012).
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141(1), 150–156 (2011).
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in Type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern. Med. 173(7), 534–539 (2013).
   PubMed Web of Science ®Google Scholar